Stock Scorecard



Stock Summary for Indivior Plc (INDV) - $25.28 as of 10/24/2025 5:30:30 PM EST

Total Score

12 out of 30

Safety Score

49 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for INDV

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for INDV

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for INDV

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for INDV

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for INDV (49 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 6
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for INDV

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update 9/30/2025 5:00:00 AM
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 9/26/2025 5:00:00 AM
Addex Appoints Bank of New York Mellon as Depositary Bank 9/23/2025 5:00:00 AM
What Makes Indivior PLC ( INDV ) a Strong Momentum Stock: Buy Now? 9/10/2025 4:00:00 PM
Durect Posts Narrower Loss in Fiscal Q2 8/13/2025 3:12:00 AM
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Almonty Indus ( NASDAQ:ALM ) , Adagene ( NASDAQ:ADAG ) 8/6/2025 12:10:00 PM
All You Need to Know About Indivior ( INDV ) Rating Upgrade to Strong Buy 8/5/2025 4:00:00 PM
Best Momentum Stock to Buy for August 5th 8/5/2025 2:00:00 PM
New Strong Buy Stocks for August 5th 8/5/2025 10:16:00 AM
Indivior ( INDV ) Q2 EPS Jumps 104% 8/1/2025 8:12:00 AM

Financial Details for INDV

Company Overview

Ticker INDV
Company Name Indivior Plc
Country USA
Description Indivior PLC is a leading global biopharmaceutical company headquartered in North Chesterfield, Virginia, specializing in the development and commercialization of innovative treatments for opioid dependence and related disorders, particularly through its proprietary buprenorphine-based therapies. The company is dedicated to improving patient outcomes by addressing the complex challenges of opioid use disorder and is committed to advancing research and development in this critical area of public health. With a robust portfolio of therapeutic solutions and a focus on patient-centric care, Indivior continues to establish itself as a pivotal player in transforming the landscape of addiction treatment.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - SPECIALTY & GENERIC
Most Recent Quarter 6/30/2025
Next Earnings Date 10/23/2025

Stock Price History

Last Day Price 25.28
Price 4 Years Ago 17.25
Last Day Price Updated 10/24/2025 5:30:30 PM EST
Last Day Volume 940,785
Average Daily Volume 1,895,534
52-Week High 25.49
52-Week Low 7.62
Last Price to 52 Week Low 231.76%

Valuation Measures

Trailing PE 29.74
Industry PE 90.61
Sector PE 41.12
5-Year Average PE -24.21
Free Cash Flow Ratio 6.18
Industry Free Cash Flow Ratio 13.66
Sector Free Cash Flow Ratio 31.25
Current Ratio Most Recent Quarter 0.90
Total Cash Per Share 4.09
Book Value Per Share Most Recent Quarter -2.06
Price to Book Ratio 145.25
Industry Price to Book Ratio 11.41
Sector Price to Book Ratio 32.29
Price to Sales Ratio Twelve Trailing Months 2.60
Industry Price to Sales Ratio Twelve Trailing Months 2.78
Sector Price to Sales Ratio Twelve Trailing Months 16.43
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 124,770,000
Market Capitalization 3,154,185,600
Institutional Ownership 82.27%

Dividends

Ex-Dividend Date 6/16/2016
Previous Dividend Amount 0.0000
Current Dividend Amount 0.4750
Total Years Dividend Increasing 2
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 2.31
Forward Annual Dividend Yield 19.85%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 100.00%
3-Year Dividend Growth Rate Percentage 143.67%
5-Year Dividend Growth Rate Percentage 143.67%
All-Time Dividend Growth Rate Percentage 196.88%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -15.50%
Annual Earnings Growth 0.00%
Reported EPS 12 Trailing Months 0.81
Reported EPS Past Year 0.92
Reported EPS Prior Year -0.07
Net Income Twelve Trailing Months 128,000,000
Net Income Past Year 2,000,000
Net Income Prior Year 2,000,000
Quarterly Revenue Growth YOY 1.00%
5-Year Revenue Growth 7.82%
Operating Margin Twelve Trailing Months 23.50%

Balance Sheet

Total Cash Most Recent Quarter 510,000,000
Total Cash Past Year 319,000,000
Total Cash Prior Year 316,000,000
Net Cash Position Most Recent Quarter 202,000,000
Net Cash Position Past Year 4,000,000
Long Term Debt Past Year 315,000,000
Long Term Debt Prior Year 236,000,000
Total Debt Most Recent Quarter 308,000,000
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter -5.16
Total Stockholder Equity Past Year -348,000,000
Total Stockholder Equity Prior Year 67,903,984
Total Stockholder Equity Most Recent Quarter -258,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 189,000,000
Free Cash Flow Per Share Twelve Trailing Months 1.51
Free Cash Flow Past Year 7,000,000
Free Cash Flow Prior Year -368,000,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.36
MACD Signal 0.30
20-Day Bollinger Lower Band 12.30
20-Day Bollinger Middle Band 20.56
20-Day Bollinger Upper Band 28.82
Beta 1.02
RSI 53.72
50-Day SMA 14.48
150-Day SMA 16.84
200-Day SMA 17.16

System

Modified 10/23/2025 2:07:49 AM EST